CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

A major challenge facing tumor-antigen targeting therapies such as chimeric antigen
receptor (CAR)–T cells is the identification of suitable targets that are specifically and …

Disease-modifying drugs have transformed the treatment options for many systemic
autoimmune diseases. However, an evolving understanding of disease mechanisms, which …

Adoptive immunotherapy utilizing natural killer (NK) cells has demonstrated remarkable
efficacy in treating hematologic malignancies. However, its clinical intervention for solid …

Immunotherapy is emerging as a promising avenue in oncology, gaining increasing
importance and offering substantial advantages when compared to chemotherapy or …

Systemic drug delivery is the current clinically preferred route for cancer therapy. However,
challenges associated with tumor localization and off-tumor toxic effects limit the clinical …

Triple-negative breast cancer (TNBC) presents treatment challenges due to a lack of
detectable surface receptors. Natural killer (NK) cell-based adaptive immunotherapy is a …

Phenylboronic acid (PBA) has been highly acknowledged as a significant cancer
recognition moiety in sialic acid-overexpressing cancer cells. In this investigation, lipid …

Targeted antineoplastic immunotherapies have achieved remarkable clinical outcomes.
However, resistance to these therapies due to target absence or antigen shedding limits …

Splittable systems have emerged as a powerful approach for the precise spatiotemporal
control of biological processes. This concept relies on splitting a functional molecule into …